N9289

NVP-231

≥98% (HPLC)

• Sinónimos: N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide, adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
• Fórmula empírica (notación de Hill): C₂₅H₂₅N₃O₂S
• Número de CAS: 362003-83-6
• Peso molecular: 431.55
• MDL number: MFCD01988824
• UNSPSC Code: 12352200
• PubChem Substance ID: 329818618
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >10 mg/mL
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
• InChI: 1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
• InChI key: MVSSJPGNLQPWSW-CIRRPZLZSA-N

Descripción

Biochem/physiol Actions

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: nwg
• flash_point_f: Not applicable
• flash_point_c: Not applicable